MaxCyte’s Flow Electroporation® Technology will support non-viral gene editing in the manufacture of Anocca’s TCR-T cell therapies ROCKVILLE, Md., July 31, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., ...
ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the ...
Samsung Biologics is moving beyond simple contract development and manufacturing (CDMO) to secure a new revenue stream through "platform licensing (L/O)" based on its own technologies. The strategy is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results